Publication of List of Manufacturers Revoked from Licensing, Manufacture of Therapeutic Goods - Homart Pharmaceuticals, Australian Red Cross Blood Services, Inverness Medical Innovations T/A Alere, Pharmaxis LTD, APHS Packaging

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia. This includes medicines, medical devices, blood and blood components, and other related products. The Act was introduced to address the need for a comprehensive regulatory system that ensures the safety, quality, and efficacy of therapeutic goods available to the public. The Therapeutic Goods Administration, as part of the Department of Health, is the body responsible for administering the Act, ensuring compliance, and protecting public health by overseeing the manufacture, importation, supply, and advertising of therapeutic goods. The policy objective of the Act is to safeguard the health of the Australian population by maintaining high standards in the therapeutic goods market. This is achieved through rigorous assessment and oversight processes, ensuring that only goods meeting the required standards are available for use.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of entities and individuals engaged in the manufacture, supply, importation, or distribution of therapeutic goods in Australia. This includes pharmaceutical drugs, medical devices, blood products, and other therapeutic items. The Act is administered by the Therapeutic Goods Administration (TGA) and is a Commonwealth Act, meaning it applies across the entire nation. It governs entities such as pharmaceutical companies, medical device manufacturers, blood services, and other businesses that handle therapeutic goods. The Act imposes strict licensing requirements for the manufacture and importation of therapeutic goods and sets out standards and controls to ensure the safety, quality, and efficacy of these products. The Act also provides mechanisms for the regulation of advertising and labelling of therapeutic goods. Certain exclusions and exemptions are provided for under specific sections of the Act, such as for small businesses or specific types of goods like blood products, which are subject to different regulatory frameworks. The application of the Act can be extended or restricted through subordinate legislation and guidelines issued by the TGA.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes provisions for the revocation of licences for the manufacture of therapeutic goods, and section 41(1)(d) specifies that the Secretary can revoke such a licence. This section provides the legal basis for the revocation notices published under the authority of Dr Harry Rothenfluh, Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration. The Act requires the Secretary to notify the public of such revocations, which is evident in the publication of the revocation of the licences held by Homart Pharmaceuticals Pty Ltd, The Australian Red Cross Blood Service, Inverness Medical Innovations Australia Pty Ltd, Pharmaxis Ltd, and APHS Packaging Pty Ltd. Each of these companies had their licences revoked at their own request, as indicated in the document. Under the Therapeutic Goods Act 1989, entities that manufacture therapeutic goods in Australia must hold a valid licence to operate. The Act sets out strict requirements for the manufacture of therapeutic goods, including quality control measures, adherence to good manufacturing practices, and compliance with relevant standards. These entities are obliged to maintain records, report incidents, and ensure that their manufacturing processes meet the regulatory standards set forth in the Act. Failure to comply with these obligations can result in the Secretary revoking their licence to manufacture therapeutic goods. The Therapeutic Goods Act 1989 also outlines various offences and penalties for breaches of its provisions. For instance, operating without a valid licence, or continuing to manufacture therapeutic goods after a licence has been revoked, can result in criminal charges. The Act provides for both civil and criminal penalties for breaches, with the severity of the penalty depending on the nature and extent of the breach. In cases of serious or repeated breaches, the maximum penalty can include substantial fines and imprisonment. The revocation notices themselves are a form of enforcement action, serving to protect public health and safety by ensuring that only compliant entities are permitted to manufacture therapeutic goods in Australia.